Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

Importance Early recognition of cognitive impairment is key to optimal dementia care. No previous research has examined the probability of developing mild cognitive impairment (MCI) or Alzheimer disease and related dementias (ADRD) at 5-year follow-up among older adult Medicare beneficiaries by receipt of an annual wellness visit (AWV). Objective To assess the association of incident AWV with the first ADRD or MCI diagnosis among older adults with Medicare fee-for-service benefits. Design, setting, and participants This retrospective population-based cohort study used 100% Texas fee-for-service Medicare data from 2015 to 2022. Participants comprised 549 516 community-dwelling Medicare beneficiaries aged 68 years or older in 2018, with complete Medicare fee-for-service Parts A and B and no Medicare Advantage plan enrollment for 2015 to 2018. Exposure Medicare AWVs. Main outcomes and measures The first MCI or ADRD diagnosis (reported as MCI or ADRD diagnosis, MCI diagnosis, and ADRD diagnosis) from the AWV index date in 2018 through December 31, 2022. Results In this cohort study of 549 516 Medicare beneficiaries with no diagnosis of MCI or ADRD in 2015 to 2017 (mean [SD] age, 76.7 [6.6] years; 289 932 women [52.8%]), 66 433 (12.1%) had an incident AWV in 2018. Annual wellness visit recipients were more likely than those who did not receive an AWV to be female, to be non-Hispanic White (followed by Hispanic, non-Hispanic Black, and other), to have more education, to reside in a metropolitan area, to have more comorbidities, and to have a primary care professional in the 12 months before the AWV index date. After propensity score matching, AWV receipt was associated with a 21% increase in MCI diagnosis (hazard ratio, 1.21 [95% CI, 1.16-1.27]) and a 4% increase in ADRD diagnosis (hazard ratio, 1.04 [95% CI, 1.02-1.06]). The increase in MCI diagnosis associated with AWV was larger when the AWV was censored or treated as a time-dependent covariate in the follow-up period. Conclusions and relevance These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. This study suggests that the Medicare AWV health policy may increase MCI identification, prompting more specialized care.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 549,516 participants. Among Medicare beneficiaries, receiving an annual wellness visit was associated with a 21% increase in MCI diagnosis and a 4% increase in ADRD diagnosis. Reported effect size: MCI diagnosis HR 1.21 (95% CI 1.16-1.27); dementia diagnosis HR 1.04 (95% CI 1.02-1.06) after an Annual Wellness Visit.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Tzeng, H. M., Raji, M. A., Shan, Y., Cram, P., & Kuo, Y. F. (2024). Annual Wellness Visits and Early Dementia Diagnosis Among Medicare Beneficiaries. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.37247

Vancouver

Tzeng HM, Raji MA, Shan Y, Cram P, Kuo YF. Annual Wellness Visits and Early Dementia Diagnosis Among Medicare Beneficiaries. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.37247. PMID: 39378037.

BibTeX

@article{tzeng2024-39378037,
  author  = {Tzeng, H. M. and Raji, M. A. and Shan, Y. and Cram, P. and Kuo, Y. F.},
  title   = {{Annual Wellness Visits and Early Dementia Diagnosis Among Medicare Beneficiaries}},
  journal = {JAMA Network Open},
  year    = {2024},
  doi     = {10.1001/jamanetworkopen.2024.37247},
  pmid    = {39378037},
  url     = {https://doi.org/10.1001/jamanetworkopen.2024.37247}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Among Medicare beneficiaries, receiving an annual wellness visit was associated with a 21% increase in MCI diagnosis and a 4% increase in ADRD diagnosis. The authors say early recognition of cognitive impairment is key to optimal dementia care.

Study details

Limitations

Single state (Texas); observational and vulnerable to healthy-user bias despite matching; a diagnosis code does not guarantee an accurate or useful diagnosis; fee-for-service only.

How this study scored 66/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 65 of the 98 points it could be judged on, which is 66 of 100. Total 66 of 100.65 of the 98 points we could judge = 66 of 100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 65 of the 98 points we could judge it on, which is 66 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA Network Open)
Journal's citation record 2 / 4 JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 4 / 4 549,516 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 29 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.2 citations a year over 4 year(s) since 2024
Impact for its field and year 3 / 6 Cited 7.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 5 other studies in this library
Still being cited 2 / 4 Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Yong‐Fang Kuo: h-index 76 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Toronto: institution h-index 1,923 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39378037)
Free to read — / 2 Access not recorded — left out of this score
Points 65 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 65 of the 98 points we could judge it on is 66 out of 100.
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Getting a diagnosis from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →